Search

Displaying results 2081 - 2090 of 4591 in total
  1. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

  2. Drug

    Iopamidol

    go.drugbank.com/drugs/DB08947
    ApprovedInvestigational

    Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.

  3. Drug

    L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

    go.drugbank.com/drugs/DB06124
    Experimental

    C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal muscle breakdown. C-101 includes a ...

  4. Drug

    Halazepam

    go.drugbank.com/drugs/DB00801
    ApprovedIllicitWithdrawn

    [A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229]

  5. Drug

    MF-300

    go.drugbank.com/drugs/DB32060
    Investigational

    As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983]

  6. Drug

    Polycarbophil

    go.drugbank.com/drugs/DB09311
    ApprovedWithdrawn

    Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali.

  7. Drug

    Cocaine

    go.drugbank.com/drugs/DB00907
    ApprovedIllicitInvestigational

    Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.

  8. Drug

    Benserazide

    go.drugbank.com/drugs/DB12783
    ApprovedInvestigational

    A decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa as it is incapable of crossing the blood-brain barrier itself but acts to prevent the formation … When levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the

  9. Drug

    Pyridostigmine

    go.drugbank.com/drugs/DB00545
    ApprovedInvestigational

    By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms.

  10. Drug

    Mebutamate

    go.drugbank.com/drugs/DB06797
    Approved

    Mebutamate is a sedative and anxiolytic drug with anti-hypertensive (blood pressure lowering) effects comparable to those of other barbiturates but is only around 1/3rd the potency of secobarbital as a